Relief Therapeutics Receives $2 Million Milestone Payment After FDA Approval of Arimoclomol
核心洞察
Relief Therapeutics (搜索) will receive a $2 million milestone payment from SWK Funding LLC following the FDA approval of Zevra Therapeutics' arimoclomol.
The FDA approved arimoclomol (MIPLYFFA) for treating neurological manifestations of Niemann-Pick Disease Type C (搜索) in patients aged 2 years and older.
This payment is part of a royalty monetization agreement where Relief received $5.75 million initially and could receive up to $5.25 million based on milestones.
Relief Therapeutics (搜索) Holding SA is set to receive a $2 million milestone payment from SWK Funding LLC this month, triggered by the U.S. Food and Drug Administration's (FDA) approval of Zevra Therapeutics Inc.’s arimoclomol. The drug, marketed as MIPLYFFA, is the first FDA-approved treatment for Niemann-Pick Disease Type C (搜索) (NPC). This payment is part of an existing royalty monetization agreement between Relief and SWK.
MIPLYFFA (arimoclomol) is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older. NPC is a rare, progressive genetic disorder characterized by impaired lipid metabolism, leading to neurological and systemic complications.
The royalty monetization agreement, previously announced, provided Relief with an initial payment of $5.75 million in August 2024. The company is eligible for up to an additional $5.25 million contingent on specific milestones. The FDA's approval of arimoclomol marks the successful completion of the first milestone, resulting in the $2 million payment. Relief remains eligible for an additional $3.25 million if OLPRUVA’s quarterly net sales reach $1.5 million by the end of the third quarter of 2025.
Relief Therapeutics (搜索) is focused on delivering innovative treatment options for select specialty, unmet, and rare diseases. The company's portfolio includes marketed products, proprietary platform technologies (TEHCLO™ and Physiomimic™), and a clinical development pipeline targeting rare skin diseases, rare metabolic disorders, and rare respiratory diseases.